IP Library Granted Patent US 10,337,017
Granted Patent B2
US 10,337,017 · App. 15/859,022 · Granted Jul 2, 2019

Method of stimulating TLR9-activated immune response

Inventors: Tsung-Hsien Chuang (Miaoli County, TW); Chao-Yang Lai (Miaoli County, TW)
Assignee: National Health Research Institutes
C12N15/117A61K39/39A61K2039/55505A61K2039/55561C12N2310/17
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,337,017
App. No.
15/859,022
Granted
Jul 2, 2019
Kind
B2
Abstract

A method of stimulating a TLR9-activated immune response or enhancing a TLR9-activated immune response to an antigen is disclosed herein. TLR9 is the cellular receptor for CpG-ODN, and current developed CpG-ODN has low activity to rabbit TLR9. Here, the method of stimulating TLR9-activated immune response by administering an effective amount of immunogenic composition comprising an antigen and a CpG-ODN comprising GACGTT or AACGTT motif was demonstrated to have potent immunostimulatory activity to rabbit TLR9, and capable of boosting a less toxic and potent antibody response in rabbits.

Claims (5)

1. A method of stimulating a TLR9-activated immune response or enhancing a TLR9-activated immune response to an antigen, comprising administering to a rabbit or a mouse an effective amount of an immunogenic composition comprising an antigen and a CpG-oligodeoxynucleotide (CpG-ODN) comprising a GACGTT motif or a AACGTT motif; wherein said CpG-ODN consists of the sequence of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 5, or SEQ ID NO: 6.

2. The method of claim 1 , wherein the administering comprises subcutaneous injection.

3. The method of claim 1 , wherein a ratio between the antigen and the CpG-ODN of the immunogenic composition is in a range from 3:50 to 10:50.

4. The method of claim 1 , wherein the immunogenic composition further comprises an aluminum hydroxide gel.

5. The method of claim 4 , wherein a concentration of the aluminum hydroxide gel is in a range of 0.2-1% (V/V).

Continuity (3)
Continuation 14906150
Provisional Application 61856268 · Jul 19, 2013
Related Publication 20180135053A1 · May 17, 2018